<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00970580</url>
  </required_header>
  <id_info>
    <org_study_id>212-LC-101</org_study_id>
    <nct_id>NCT00970580</nct_id>
  </id_info>
  <brief_title>A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase 1b, Open-Label, Dose-Escalation Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Treatment-Naive, Stage IIIB/IV Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether BIIB022, Paclitaxel and Carboplatin are
      effective in the treatment of Treatment-Naive, Stage IIIB/IV Non-Small Cell Lung Cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of BIIB022 in combination with paclitaxel and carboplatin</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>BIIB022 in Combination with Paclitaxel and Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIIB022 in Combination with Paclitaxel and Carboplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIIB022 With Paclitaxel and Carboplatin</intervention_name>
    <description>Escalating doses of BIIB022 with fixed dose and schedule of paclitaxel and carboplatin</description>
    <arm_group_label>BIIB022 in Combination with Paclitaxel and Carboplatin</arm_group_label>
    <other_name>Taxol</other_name>
    <other_name>Paraplatin</other_name>
    <other_name>BIIB022</other_name>
    <other_name>Taxane</other_name>
    <other_name>Anti-IGF-1R</other_name>
    <other_name>Cytotoxic</other_name>
    <other_name>Mitotic Inhibitor</other_name>
    <other_name>IGF-1R</other_name>
    <other_name>Alkylating agent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;/= 18 years old

          -  Treatment-naive Stage IIIB/IV Non-Small Cell Lung Cancer

          -  ECOG Performance Status 0 or 1

        Exclusion Criteria:

          -  History of another primary cancer within 3 years

          -  Any prior or concurrent investigational or standard therapy for treatment of NSCLC

          -  Prior anti-IGF-1R therapy

          -  Unstable diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Resesarch Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Resesarch Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Resesarch Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2009</study_first_submitted>
  <study_first_submitted_qc>September 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2009</study_first_posted>
  <last_update_submitted>September 12, 2013</last_update_submitted>
  <last_update_submitted_qc>September 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2013</last_update_posted>
  <responsible_party>
    <name_title>Therese Senta-McMillian, Clinical Team Manager</name_title>
    <organization>PRA International</organization>
  </responsible_party>
  <keyword>BIIB022</keyword>
  <keyword>Stage IV</keyword>
  <keyword>Taxol</keyword>
  <keyword>Stage IIIB</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Non Small Cell Lung Cancer</keyword>
  <keyword>Treatment Naive</keyword>
  <keyword>Anti IGF1R</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Open Label</keyword>
  <keyword>IGF1R</keyword>
  <keyword>Paraplatin</keyword>
  <keyword>Cytotoxic</keyword>
  <keyword>Mitotic Inhibitor</keyword>
  <keyword>Taxane</keyword>
  <keyword>Alkylating agent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Antimitotic Agents</mesh_term>
    <mesh_term>Taxane</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Mecasermin</mesh_term>
    <mesh_term>Alkylating Agents</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

